公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Leukocyte cell-derived chemotaxin 2 retards non-small cell lung cancer progression through antagonizing MET and EGFR activities | Hung W.-Y.; Chang J.-H.; Cheng Y.; Chen C.-K.; Chen J.-Q.; KUO-TAI HUA ; Cheng C.-W.; Hsiao M.; Chung C.-L.; Lee W.-J.; Chien M.-H. | Cellular Physiology and Biochemistry | 12 | 11 | |
2015 | Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial | Cainap C.; Qin S.; Huang W.-T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.-K.; PEI-JER CHEN ; Toh H.-C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S. | Journal of Clinical Oncology | 476 | 453 | |
2018 | Novel electromagnetic targeting system for navigating surgery in endobronchoscopy | Chen C.; CHING-KAI LIN ; Cheng Y.; Chung T.; Chang C.; Tsai S.; Chen J.; Lin X. | 2018 IEEE International Magnetic Conference, INTERMAG 2018 | 2 | 0 | |
1998 | Occiput-cervical fusion for symptomatic atlantoaxial subluxation in a 32-month-old child with Down syndrome: A case report | SHENG-HONG TSENG ; Cheng Y. | Spinal Cord | 4 | 5 | |
2020 | A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis | CHIH-HSIN YANG ; Cheng Y.; Murakami H.; PAN-CHYR YANG ; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M. | Journal of Thoracic Oncology | 29 | 28 | |
2016 | Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations | Cheng Y.; Murakami H; PAN-CHYR YANG ; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG | Journal of Clinical Oncology | 160 | 134 | |
2020 | Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial | Xu J.; Xu R.-H.; Qin S.; Pan H.; Bai Y.; Chi Y.; Wang L.; Bi F.; Cheng Y.; Liu T.; Ma D.; Shen L.; Ba Y.; Liang J.; Wang X.; Yau T.C.C.; Ma B.B.; KUN-HUEI YEH ; Lin J.-K.; Kappeler C.; Shapiro J.; Kalmus J.; Li J. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 5 | |
2015 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial | Li J.; Qin S.; Xu R.; Yau T.C.C.; Ma B.; Pan H.; Xu J.; Bai Y.; Chi Y.; Wang L.; KUN-HUEI YEH ; Bi F.; Cheng Y.; Le A.T.; Lin J.-K.; Liu T.; Ma D.; Kappeler C.; Kalmus J.; Kim T.W. | The Lancet Oncology | 597 | 536 | |
2017 | Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al | CHIH-HSIN YANG ; Puri T; Orlando M; Cheng Y. | Journal of Clinical Oncology | 0 | 0 | |
2016 | Secondary neoplasms arising from nevus sebaceus: A retrospective study of 450 cases in Taiwan | Hsu M.-C.; JAU-YU LIAU ; Hong J.-L.; Cheng Y.; YI-HUA LIAO ; JAU-SHIUH CHEN ; YI-SHUAN SHEEN ; JIN-BON HONG | Journal of Dermatology | 40 | 34 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 |